The American Journal of Medicine
Volume 121, Issue 8, Supplement 1 , Pages S23-S31 , August 2008

Management of Hypertension and Cerebrovascular Disease in the Elderly

  • Laura Pedelty, MD, PhD

      Affiliations

    • Department of Neurology, University of Illinois at Chicago Circle, Chicago, Illinois, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Laura Pedelty, MD, PhD, Department of Neurology, University of Illinois at Chicago Circle, 912 South Wood Street, MC 796, Chicago, Illinois 60612.
    • ,
  • Philip B. Gorelick, MD, MPH

      Affiliations

    • Department of Neurology, University of Illinois at Chicago Circle, Chicago, Illinois, USA
    • School of Public Health, University of Illinois at Chicago Circle, Chicago, Illinois, USA

References 

  1. World Health Organization. Global burden of stroke. In:  MacKay J,  Mensah G editor. The Atlas of Heart Disease and Stroke. 2004;http://www.who.int/cardiovascular_diseases/resources/atlas/en/Accessed October 27, 2007
  2. Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke. 2005;36:720–723
  3. Tatemichi TK, Paik M, Bagiella E, et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology. 1994;44:1885–1891
  4. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901–2906
  5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  6. van Wijk I, Kappelle LJ, van Gijn J, et al. LiLAC Study Group Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365:2098–2104
  7. Goldstein LB, Adams A, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group, Cardiovascular Nursing Council, Clinical Cardiology Council, Nutrition, Physical Activity, and Metabolism Council, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873–e923
  8. Sacco RL, Adams A, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409–e449
  9. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  10. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446
  11. Black HR. The paradigm has shifted to systolic blood pressure. J Hum Hypertens. 2004;18(suppl 2):S3–S7
  12. Kannel WB, Dawber TR, Sorlie P, Wolf PA. Components of blood pressure and risk of atherothrombotic brain infarction: the Framingham study. Stroke. 1976;7:327–331
  13. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869–874
  14. Román GC. Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis. 2005;20(suppl 2):91–100
  15. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426–436
  16. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215–1222
  17. Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? (A meta-analysis of hypertension treatment trials). Arch Fam Med. 1995;4:943–949
  18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the elderly Program (SHEP). JAMA. 1991;265:3255–3264
  19. Perry HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465–471
  20. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension–2 study. Lancet. 1999;354:1751–1756
  21. Ekbom T, Linjer E, Hedner T, et al. Cardiovascular events in elderly patients with isolated systolic hypertension: a subgroup analysis of treatment strategies in STOP-Hypertension–2. Blood Press. 2004;13:137–141
  22. Staessen JA, Fagard R, Thijs L, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764
  23. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347–1351
  24. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens. 2006;24:1907–1914
  25. Li C, Engström G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke. 2005;36:725–730
  26. Beckett NS, Connor M, Sadler JD, Fletcher AE, Bulpitt CJ HYVET Investigators. Orthostatic fall in blood pressure in the very elderly hyperensive: results from the Hypertension in the Very Elderly Trial (HYVET)—pilot. 1999 J Hum Hypertens. 1999;13:839–840
  27. Gueyffier F, Bulpitt C, Boissel JP, et al. INDANA Group Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet. 1999;353:793–796
  28. Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M, et al. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation. 2007;115:2969–2975
  29. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am. 2002;86:477–499
  30. Dufouil C, Chalmers J, Coskun O, et al. PROGRESS MRI Substudy Investigators Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 2005;112:1644–1650
  31. Roman GC. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res. 2004;6:454–458
  32. Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord. 2001;12:33–39
  33. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996;312:805–808
  34. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61:1667–1672
  35. van Dijk EJ, Breteler MM, Schmidt R, et al. CASCADE Consortium The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension. 2004;44:625–630
  36. Alves de Moraes S, Szklo M, Knopman D, Sato R. The relationship between temporal changes in blood pressure and changes in cognitive function: Atherosclerosis Risk in Communities (ARIC) study. Prev Med. 2002;35:258–263
  37. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22:407–412
  38. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60:223–228
  39. Anson O, Paran E. Hypertension and cognitive functioning among the elderly: an overview. Am J Ther. 2005;12:359–365
  40. Goldstein LB. Blood pressure management in patients with acute ischemic stroke. Hypertension. 2004;43:137–141
  41. Potter J, Robinson T, Ford G, et al. CHHIPS Trial Group CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design. J Hypertens. 2005;23:649–655
  42. Ohkubo T, Hozawa A, Nagai K, et al. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens. 2000;18:847–854
  43. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203–208
  44. Kario K, Ishikawa J, Pickering TG, et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006;29:581–587
  45. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers. J Hum Hypertens. 2002;16(suppl 3):S64–S70
  46. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004;43:1343–1347
  47. Magy L, Vincent F, Faure S, et al. The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des. 2005;11:3275–3291
  48. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens. 2006;20:101–108
  49. Makino I, Shibata K, Ohgami Y, Fujiwara M, Furukawa T. Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides. 1996;30:596–601
  50. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke. 2004;35:348–350
  51. Dahlof B. Prospects for the prevention of stroke. J Hypertens Suppl. 2006;24:S3–S9
  52. Nilsson PM. Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs. Drugs Aging. 2005;22:517–524
  53. Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging. 2006;23:131–155
  54. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  55. Kjeldsen SE, Dahlöf B, Devereux RB, et al. LIFE Study Group Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491–1498
  56. Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–886
  57. Papademetriou V, Farsang C, Elmfeldt D, et al. Study on Cognition and Prognosis in the Elderly Study Group Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175–1180
  58. Schrader J, Lüders S, Kulschewski A, et al. MOSES Study Group Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–1226
  59. Boutitie F, Oprisiu R, Achard JM, et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? (A meta-analysis of trials according to treatment with potentially different effects on angiotensin II). J Hypertens. 2007;25:1543–1553
  60. Diener HC, Sacco R, Yusuf S Steering Committee of the PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23:368–380
  61. Sleight P. The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol. 2005;42(suppl 1):S50–S56
  62. JATOS Study Group. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res. 2005;28:513–520
  63. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898
  64. Peters R, Beckett N, Nunes M, et al. A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging. 2006;23:83–92

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00505-6

doi: 10.1016/j.amjmed.2008.05.019

The American Journal of Medicine
Volume 121, Issue 8, Supplement 1 , Pages S23-S31 , August 2008

Article Tools

* Image Usage & Resolution